Home › Chronic Lymphocytic Leukemia › California › San Diego

Pag-aaral pangklinika para sa Chronic Lymphocytic Leukemia sa San Diego, CA

Isang pag-aaral para sa Chronic Lymphocytic Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa San Diego. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Nagre-recruitPhase 1/2

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla · 11 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05006716

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Nagre-recruitPhase 3

Kaiser Permanente-San Diego Zion, San Diego

Edad 65 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07321652

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Nagre-recruitPhase 3

Kaiser Permanente-San Diego Zion, San Diego

Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT04269902

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Nagre-recruitPhase 1/2

Research Site, La Jolla · 11 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06542250

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Nagre-recruitPhase 3

Scripps Prebys Cancer Center, San Diego

Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06846671

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Nagre-recruitPhase 3

Scripps Prebys Cancer Center, San Diego

Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06943872

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Nagre-recruitPhase 3

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla · 11 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06973187

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Nagre-recruitPhase 3

Moores Cancer Center ( Site 0003), La Jolla · 11 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06136559

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Nagre-recruitPhase 2

Scripps Health, San Diego

Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07221500

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Nagre-recruitPhase 2

Moores Cancer Center at UC San Diego /ID# 230157, La Jolla · 11 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Peb 9, 2026 · NCT04895436

Pag-aaral para sa Chronic Lymphocytic Leukemia sa ibang lungsod

Iba pang pag-aaral sa San Diego

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.